| PADAGIS-ISRAEL-PHARMACEUTICALS-LTD |
PADAGIS-ISRAEL-PHARMACEUTICALS-LTD |
85%
|
NOTE 8 — COLLABORATION AGREEMENTS: a. In 2007, the Company sublicensed rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is ent… |
| ACRS |
Aclaris Therapeutics, Inc. |
72%
|
Reciprocal relationship from ACRS graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from ACRS g… |
| ACRS |
Aclaris Therapeutics, Inc. |
72%
|
se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mexico and Israel. These registrations cover potential brand names for our Epsolay i… |
| BHC |
Bausch Health Companies Inc. |
72%
|
se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mexico and Israel. These registrations cover potential brand names for our Epsolay i… |
| BHC |
Bausch Health Companies Inc. |
72%
|
Reciprocal relationship from BHC graph: Reciprocal relationship from SLGL graph: se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mex… |
| NVSEF |
Novartis AG |
72%
|
se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mexico and Israel. These registrations cover potential brand names for our Epsolay i… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from SLGL graph: se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, M… |
| ORANY |
ORANY |
72%
|
se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mexico and Israel. These registrations cover potential brand names for our Epsolay i… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from ORAN… |
| ACLARIS-THERAPEUTICS-INC-AKORN-INC |
ACLARIS-THERAPEUTICS-INC-AKORN-INC |
62%
|
ay’ is registered in Europe (including the United Kingdom), Canada, Australia, Iceland, Montenegro, Norway, Serbia, Mexico, and Israel. Epsolay was also filed for registration in Bosnia & Herzegovina… |
| ALMIRALL-S-A-AQUA-PHARMACEUTICALS-LLC |
ALMIRALL-S-A-AQUA-PHARMACEUTICALS-LLC |
62%
|
ay’ is registered in Europe (including the United Kingdom), Canada, Australia, Iceland, Montenegro, Norway, Serbia, Mexico, and Israel. Epsolay was also filed for registration in Bosnia & Herzegovina… |
| ARCUTIS-BIOTHERAPEUTICS-BAUSCH-HEALTH-COMPANIES- |
ARCUTIS-BIOTHERAPEUTICS-BAUSCH-HEALTH-COMPANIES- |
62%
|
ay’ is registered in Europe (including the United Kingdom), Canada, Australia, Iceland, Montenegro, Norway, Serbia, Mexico, and Israel. Epsolay was also filed for registration in Bosnia & Herzegovina… |
| ARKIN-DERMATOLOGY-LTD |
ARKIN-DERMATOLOGY-LTD |
62%
|
erman * * Sharon Kochan * * Yuval Yanai * * All directors and executive officers as a group (10 persons)(4) 2,022,181 65.73 % * Less than 1%. (1) M. Arkin Dermatology directly owns 1,606,856 ordinary… |
| CASSIOPEA-SPA-ORGANON-GALDERMA-PHARMA-S-A-GLENMA |
CASSIOPEA-SPA-ORGANON-GALDERMA-PHARMA-S-A-GLENMA |
62%
|
ay’ is registered in Europe (including the United Kingdom), Canada, Australia, Iceland, Montenegro, Norway, Serbia, Mexico, and Israel. Epsolay was also filed for registration in Bosnia & Herzegovina… |
| EQUINITI-TRUST-COMPANY-LLC |
EQUINITI-TRUST-COMPANY-LLC |
62%
|
erman * * Sharon Kochan * * Yuval Yanai * * All directors and executive officers as a group (10 persons)(4) 2,022,181 65.73 % * Less than 1%. (1) M. Arkin Dermatology directly owns 1,606,856 ordinary… |
| M-ARKIN-DERMATOLOGY-LTD |
M-ARKIN-DERMATOLOGY-LTD |
62%
|
eeded, based on agreed upon rates. In return, the Company is to receive payments of up to $ 10 million (including amounts contingent on achieving certain milestones) and up to $ 5 million as royalty … |
| MAYNE-PHARMA-GROUP-LIMITED |
MAYNE-PHARMA-GROUP-LIMITED |
62%
|
eeded, based on agreed upon rates. In return, the Company is to receive payments of up to $ 10 million (including amounts contingent on achieving certain milestones) and up to $ 5 million as royalty … |
| MEDICIS-PHARMACEUTICAL-CORPORATION |
MEDICIS-PHARMACEUTICAL-CORPORATION |
62%
|
ormation to support our research, development and other activities. Our failure to comply with the data privacy and security principles set forth in HIPAA, or a breach of health information or person… |
| MPC |
Marathon Petroleum Corporation |
62%
|
Reciprocal relationship from MPC graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from MPC graph: Reciprocal relationship from SLGL graph: ormation to support our research, dev… |
| OPALEYE-MANAGEMENT-INC |
OPALEYE-MANAGEMENT-INC |
62%
|
erman * * Sharon Kochan * * Yuval Yanai * * All directors and executive officers as a group (10 persons)(4) 2,022,181 65.73 % * Less than 1%. (1) M. Arkin Dermatology directly owns 1,606,856 ordinary… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
ements that we are required to meet in order to maintain a listing on the Nasdaq. Our failure to meet these requirements may result in our securities being delisted from Nasdaq. If our ordinary share… |
| PHOENIX-HOLDING-LTD |
PHOENIX-HOLDING-LTD |
62%
|
erman * * Sharon Kochan * * Yuval Yanai * * All directors and executive officers as a group (10 persons)(4) 2,022,181 65.73 % * Less than 1%. (1) M. Arkin Dermatology directly owns 1,606,856 ordinary… |
| ROYALTY-SECURITY-LLC |
ROYALTY-SECURITY-LLC |
62%
|
method of treatment with SGT-610 in US, Europe, United Arab Emirates, The African Regional Intellectual Property Organization (ARIPO), Australia, Brazil, Canada, Chile, China, Eurasia, Israel, Japan,… |
| SEARCHLIGHT-PHARMA-INC |
SEARCHLIGHT-PHARMA-INC |
62%
|
. The Company has identified one performance obligation in the Termination Agreement. Revenue from sale of IP is recognized at a point in time, upon transfer of control over the sale of the IP to Pad… |
